PROVEN RESULTS
IN METASTATIC PROSTATE CANCER THAT RESPONDS TO ADT*
NUBEQA® offers options for a personalized treatment decision in prostate cancer that has spread (metastatic) and responds to ADT
In two different clinical studies, NUBEQA delivered proven results. You and your doctor can determine if taking NUBEQA with or without chemotherapy† may be right for you.
*ADT refers to a medical or surgical treatment that lowers testosterone.
†Chemotherapy=docetaxel.
At the time of analysis, 29% (128 out of 446) of men taking NUBEQA + ADT had cancer worsening via scans or were no longer living compared to 42% (94 out of 223) of men taking ADT alone.
At the time of analysis, 35% (229 out of 651) of men taking NUBEQA + ADT + chemotherapy were no longer living compared to 46% (304 out of 654) of men taking ADT + chemotherapy.
‡rPFS is measured by the cancer worsening via scans or the participant no longer living.
§Median is the middle value in a set of numbers, not the average.
¶Docetaxel is an intravenous (IV) chemotherapy infusion that may be used in combination with NUBEQA. Docetaxel 75 mg/m2 for 21 days for 6 cycles. Note 21 days is one cycle.
More about these clinical studies:
Select a NUBEQA treatment option to learn more about the study
NUBEQA was added to ADT in men with metastatic prostate cancer that responds to ADT. NUBEQA results were compared to results in men taking ADT alone.
Select inclusion criteria:
- 669 men between the ages of 43 and 93 were included in the study, with a median age of 70
- 77% of men in the study had stage M1b prostate cancer, meaning their cancer had spread to their bones
- 50% (333 men) were still physically able to do things they could before their disease#
- 47% (316 men) were restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature#
Two thirds of the men in the study took NUBEQA + ADT, while the remaining men took ADT alone.
NUBEQA group (446 men)
NUBEQA + ADT
Placebo group (223 men)
ADT
#According to the Eastern Cooperative Oncology Group Performance Status (ECOG PS) scale.
NUBEQA was added to ADT + chemotherapy in men with metastatic prostate cancer that responds to ADT. NUBEQA results were compared to results in men taking ADT + chemotherapy alone.
Select inclusion criteria:
- 1306 men between the ages of 41 and 89 were included in the ARASENS study, with a median age of 67
- 83% of men in the study had stage M1b prostate cancer, meaning their cancer had spread to their bones
- 71% (928 men) were still physically able to do things they could before their disease||
About half of the men in the study took NUBEQA + ADT + chemotherapy while the other half did not.
NUBEQA group (651 men)
NUBEQA + ADT + chemotherapy
Placebo group (655 men)
ADT + chemotherapy
||According to the Eastern Cooperative Oncology Group Performance Status (ECOG PS) scale. 29% of patients had an ECOG performance status score of 1, meaning they were restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature.
Adding NUBEQA to ADT also delayed pain progression**
It took significantly longer for pain to get worse for men who took NUBEQA + ADT compared with men who took ADT alone.
**Pain progression was defined as:
- An increase of 2 or more points of the worst pain felt in a 24-hour period, measured twice in a row, 4 weeks apart, OR an initiation of opioids for at least 7 days in a row for patients without pain
- An increase of 2 or more points, from a pain score of 4 or more, of the worst pain felt in a 24-hour period, measured twice in a row, 4 weeks apart, OR an initiation of opioids for at least 7 days in a row for patients with pain and a pain score of 1 or more
Patients who used opioids within 4 weeks were removed from the analysis, with 19% removed from the NUBEQA + docetaxel arm and 18% removed from the placebo + docetaxel arm.
